1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Pharmaron Beijing Co., Ltd.
  6. Summary
    300759   CNE100003JW4

PHARMARON BEIJING CO., LTD.

(300759)
  Report
End-of-day quote Shenzhen Stock Exchange  -  2022-07-03
102.00 CNY   +6.54%
06/14Pharmaron Cuts Conversion Price of Zero-Coupon Convertible Bonds Due 2026
MT
06/08Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on June 14, 2022
CI
06/01Pharmaron Beijing Co., Ltd. Approves Cash Dividend, Payable on 12 July 2022
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/04/2022 Date
93.24 94.36 95.22 95.74 102 Last
5967413 6383708 4289533 3153934 10173010 Volume
-1.76% +1.20% +0.91% +0.55% +6.54% Change
Estimated financial data (e)
Sales 2022 10 125 M 1 511 M 1 511 M
Net income 2022 2 092 M 312 M 312 M
Net cash position 2022 268 M 39,9 M 39,9 M
P/E ratio 2022 58,2x
Yield 2022 0,35%
Sales 2023 13 546 M 2 022 M 2 022 M
Net income 2023 2 829 M 422 M 422 M
Net cash position 2023 836 M 125 M 125 M
P/E ratio 2023 42,9x
Yield 2023 0,48%
Capitalization 115 B 17 200 M 17 200 M
EV / Sales 2022 11,4x
EV / Sales 2023 8,45x
Nbr of Employees -
Free-Float 30,6%
More Financials
Company
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (63.3%); - manufacturing and control of chemistry (24.1%); - in vitro biology services (12.2%); Net sales are distributed geographically as follows: China (12.7%), Asia (4%), North America (58.8%),... 
More about the company
Ratings of Pharmaron Beijing Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about PHARMARON BEIJING CO., LTD.
06/14Pharmaron Cuts Conversion Price of Zero-Coupon Convertible Bonds Due 2026
MT
06/08Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2021, Pay..
CI
06/01Pharmaron Beijing Co., Ltd. Approves Cash Dividend, Payable on 12 July 2022
CI
05/24Pharmaron Acquires Commercial API Manufacturing Facility in the United States
BU
05/24Pharmaron Beijing Co., Limited Acquires Commercial API Manufacturing Facility in the Un..
CI
05/24Pharmaron Beijing Co., Ltd. has entered into a definitive Asset Purchase Agreement to a..
CI
05/08Pharmaron Beijing Concludes Nearly $13 Million Purchase of Lab Animal Breeder
MT
05/06Pharmaron Beijing Co., Ltd. completed the acquisition of 100% equity interest in Beijin..
CI
04/29Pharmaron Beijing Co., Ltd. Proposes Final Cash Dividend for the Financial Year Ended D..
CI
04/28Pharmaron Beijing Co., Ltd. Reports Earnings Results for the First Quarter Ended March ..
CI
04/19Pharmaron Beijing Eyes Issuance of Additional Shares in Hong Kong
MT
04/18Hangzhou Xiaofu Technology Co., Ltd. announced that it has received $3.140000 million i..
CI
04/01UBS Adjusts Pharmaron's Price Target to HK$149 From HK$240, Keeps at Buy
MT
03/28Pharmaron Beijing Eyes $13 Million Acquisition of Laboratory Animals Breeder
MT
03/28Pharmaron Beijing Co., Ltd. intends to acquire Beijing AnniKeeper Biotechnology Co., Lt..
CI
More news
News in other languages on PHARMARON BEIJING CO., LTD.
06/08Pharmaron Beijing Co., Ltd. annonce le dividende final sur les actions A pour l'année 2..
06/01Pharmaron Beijing Co., Ltd. approuve le dividende en espèces
05/24Pharmaron Beijing Co., Limited acquiert une installation de fabrication d'API commercia..
05/06PHARMARON BEIJING CO., LTD. (SZSE : 300759) a finalisé l'acquisition de 100% des parts de ..
04/29Pharmaron Beijing Co., Ltd. Propose un dividende final en espèces pour l'exercice finan..
More news
Analyst Recommendations on PHARMARON BEIJING CO., LTD.
More recommendations
Chart PHARMARON BEIJING CO., LTD.
Duration : Period :
Pharmaron Beijing Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PHARMARON BEIJING CO., LTD.
Short TermMid-TermLong Term
TrendsBullishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 102,00 CNY
Average target price 105,08 CNY
Spread / Average Target 3,02%
EPS Revisions
Managers and Directors
Bo Liang Lou Chairman & Chief Executive Officer
Shing Chung Li Chief Financial Officer & Board Secretary
Ke Xin Yang Chairman-Supervisory Board & Vice President
Hua Yang Chief Scientific Officer
Xiao Qiang Lou Chief Operating Officer & Executive Director
Sector and Competitors
1st jan.Capi. (M$)
PHARMARON BEIJING CO., LTD.8.30%17 200
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.83%40 011
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 031